Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reversal Of Fortune For German Pharma As Bundesrat Supports Enhanced Drug Price Transparency

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s upper house of parliament, the Bundesrat, has decided after considerable wrangling that negotiated and discounted reimbursement prices of drugs sold in Europe’s biggest market will be made public, virtually ensuring that further price erosion will spread across the region.

You may also be interested in...



German Pharma Fears Drug Prescribing Report Will Be Used To Force Down Prices Again

Drug makers in Germany say this year’s widely-referenced Pharmaceutical Prescribing Report contains misleading data and warn it will be used to suppress prices even further, stifling innovation and restricting patient access to drugs.

German Joy For Pharma As Drug Discount Prices Stay Hidden

The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.

Amended AMNOG Sees New Life Breathed Into Trajenta Reimbursement Bid In Germany

Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel